Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Nivolumab in the Treatment of Recurrent or Refractory Pediatric Brain Tumors: A Single Institutional Experience.

Gorsi HS, Malicki DM, Barsan V, Tumblin M, Yeh-Nayre L, Milburn M, Elster JD, Crawford JR.

J Pediatr Hematol Oncol. 2018 Oct 23. doi: 10.1097/MPH.0000000000001339. [Epub ahead of print]

PMID:
30681550
2.

Retrospective study of nivolumab for patients with recurrent high grade gliomas.

Mantica M, Pritchard A, Lieberman F, Drappatz J.

J Neurooncol. 2018 Sep;139(3):625-631. doi: 10.1007/s11060-018-2907-4. Epub 2018 May 19.

PMID:
29779086
3.

A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.

Fouladi M, Nicholson HS, Zhou T, Laningham F, Helton KJ, Holmes E, Cohen K, Speights RA, Wright J, Pollack IF; Children's Oncology Group.

Cancer. 2007 Dec 1;110(11):2535-41.

4.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

5.

Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.

Wetmore C, Daryani VM, Billups CA, Boyett JM, Leary S, Tanos R, Goldsmith KC, Stewart CF, Blaney SM, Gajjar A.

Cancer Med. 2016 Jul;5(7):1416-24. doi: 10.1002/cam4.713. Epub 2016 Apr 25.

6.

Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.

Turner CD, Gururangan S, Eastwood J, Bottom K, Watral M, Beason R, McLendon RE, Friedman AH, Tourt-Uhlig S, Miller LL, Friedman HS.

Neuro Oncol. 2002 Apr;4(2):102-8. doi: 10.1093/neuonc/4.2.109.

7.

Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.

Li H, Ma W, Yoneda KY, Moore EH, Zhang Y, Pu LL, Frampton GM, Molmen M, Stephens PJ, Li T.

J Hematol Oncol. 2017 Feb 28;10(1):64. doi: 10.1186/s13045-017-0433-z.

8.

Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas.

Reiss SN, Yerram P, Modelevsky L, Grommes C.

J Immunother Cancer. 2017 Dec 19;5(1):99. doi: 10.1186/s40425-017-0302-x.

9.

Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.

AlHarbi M, Ali Mobark N, AlMubarak L, Aljelaify R, AlSaeed M, Almutairi A, Alqubaishi F, Hussain ME, Balbaid AAO, Said Marie A, AlSubaie L, AlShieban S, alTassan N, Ramkissoon SH, Abedalthagafi M.

Oncologist. 2018 Dec;23(12):1401-1406. doi: 10.1634/theoncologist.2018-0163. Epub 2018 Aug 13.

PMID:
30104292
10.

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators.

N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.

11.

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A.

Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334.

PMID:
30165371
12.

Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.

Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, Kun L, Kadota R.

J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):277-81.

PMID:
11464982
13.

Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.

Gorsi HS, Khanna PC, Tumblin M, Yeh-Nayre L, Milburn M, Elster JD, Crawford JR.

Pediatr Blood Cancer. 2018 Sep;65(9):e27234. doi: 10.1002/pbc.27234. Epub 2018 May 11.

PMID:
29750399
14.

Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.

Okada K, Yamasaki K, Tanaka C, Fujisaki H, Osugi Y, Hara J.

Jpn J Clin Oncol. 2013 Nov;43(11):1073-9. doi: 10.1093/jjco/hyt124. Epub 2013 Sep 3.

PMID:
24002900
15.

The clinical utility of tumor mutational burden in non-small cell lung cancer.

Greillier L, Tomasini P, Barlesi F.

Transl Lung Cancer Res. 2018 Dec;7(6):639-646. doi: 10.21037/tlcr.2018.10.08. Review.

16.

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K.

Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183.

PMID:
28407039
17.

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Mol Cancer Ther. 2017 Nov;16(11):2598-2608. doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.

18.

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD.

Lancet Oncol. 2017 Mar;18(3):312-322. doi: 10.1016/S1470-2045(17)30065-7. Epub 2017 Jan 26.

PMID:
28131785
19.

Recurrent pediatric central nervous system low-grade gliomas: the role of surveillance neuroimaging in asymptomatic children.

Udaka YT, Yeh-Nayre LA, Amene CS, VandenBerg SR, Levy ML, Crawford JR.

J Neurosurg Pediatr. 2013 Feb;11(2):119-26. doi: 10.3171/2012.10.PEDS12307. Epub 2012 Nov 16.

PMID:
23157391
20.

Radiotherapy for pediatric central nervous system tumors: a regional cancer centre experience.

Bauman G, Fisher B, Cairney E, Ranger A, Dar AR, Ross J, Stitt L, MacDonald D.

J Neurooncol. 2004 Jul;68(3):285-94. Review.

PMID:
15332333

Supplemental Content

Support Center